Literature DB >> 3015386

Quantitative immunological detection of estrogen receptors in nuclear pellets from human breast cancer biopsies.

S M Thorpe, A E Lykkesfeldt, A Vinterby, M Lonsdorfer.   

Abstract

A rapid, convenient method for the quantitative determination of estrogen receptors (ER) under high salt (0.6 M KCl) conditions (such as in extracts of nuclear pellets from human breast cancer biopsies) using a commercially available kit [estrogen receptor enzyme immunoassay (ER-EIA) Monoclonal; Abbott] is described. This assay has been validated using breast tumor cytosol ER preparations. It determines total (both occupied and unoccupied) ER, it is insensitive to KCl at concentrations up to 0.8 M, and it can be used with ER preparations having very low protein concentrations. Results obtained using the ER-EIA method for breast tumor nuclear extracts have been compared to those obtained using the hydroxylapatite method, and higher values have been found using the ER-EIA method. The reasons for this discrepancy may be due to: the sensitivity of ER binding to hydroxylapatite in high concentrations of KCl; the temperature dependent degradation of the receptor complex at 30 degrees C, the temperature commonly used to achieve exchange between radioactive estradiol and the endogenously bound estradiol; and possible detection of immunoreactive, but non-ligand-binding forms of ER. The possibility that occurrence of "free" receptors in high salt extracts from nuclear pellets may be an artifact is discussed. The availability of this ER-EIA suitable for nuclear ER determinations opens the possibility of extending correlations between the clinical course of breast cancer and the levels of the ER form (nuclear) that are thought to be of greatest physiological significance.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015386

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Experience of the E.O.R.T.C. Receptor Group.

Authors:  M A Blankenstein
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

2.  Immuno-biochemical assay for determination of nuclear steroid receptors during tamoxifen therapy.

Authors:  A Vering; A Vockel; M Stegmüller; H G Bender
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Do multiple oestrogen receptor assays give significant additional information for the management of breast cancer?

Authors:  L Castagnetta; A Traina; A Di Carlo; G Carruba; M Lo Casto; M Mesiti; R Leake
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

4.  Oestrogen receptor negative-progesterone receptor positive phenotype in 1,211 breast tumours.

Authors:  M F Pichon; E Milgrom
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

5.  Effect of alcohol ingestion on carcinogenesis by synthetic estrogen and progestin in the rat liver.

Authors:  K Yamagiwa; S Higashi; R Mizumoto
Journal:  Jpn J Cancer Res       Date:  1991-07

6.  Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.

Authors:  S Noguchi; H Yamamoto; H Inaji; S Imaoka; H Koyama
Journal:  Jpn J Cancer Res       Date:  1989-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.